210 related articles for article (PubMed ID: 26553686)
1. Meningococcal Seroepidemiology 1 Year After the PsA-TT Mass Immunization Campaign in Burkina Faso.
Tall H; Yaro S; Kpoda HB; Ouangraoua S; Trotter CL; Njanpop Lafourcade BM; Findlow H; Bai X; Martin C; Nwakamma I; Ouedraogo JB; Gessner BD; Borrow R; Mueller JE
Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S540-6. PubMed ID: 26553686
[TBL] [Abstract][Full Text] [Related]
2. Population-Level Persistence of Immunity 2 Years After the PsA-TT Mass-Vaccination Campaign in Mali.
Basta NE; Borrow R; Berthe A; Dembélé AT; Onwuchekwa U; Townsend K; Boukary RM; Mabey L; Findlow H; Bai X; Sow SO
Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S547-53. PubMed ID: 26553687
[TBL] [Abstract][Full Text] [Related]
3. Antibody Persistence at the Population Level 5 Years After Mass Vaccination With Meningococcal Serogroup A Conjugate Vaccine (PsA-TT) in Burkina Faso: Need for a Booster Campaign?
Yaro S; Njanpop Lafourcade BM; Ouangraoua S; Ouoba A; Kpoda H; Findlow H; Tall H; Seanehia J; Martin C; Ouedraogo JB; Gessner B; Meda N; Borrow R; Trotter C; Mueller JE
Clin Infect Dis; 2019 Jan; 68(3):435-443. PubMed ID: 30481265
[TBL] [Abstract][Full Text] [Related]
4. Serogroup A meningococcal conjugate (PsA-TT) vaccine coverage and measles vaccine coverage in Burkina Faso--implications for introduction of PsA-TT into the Expanded Programme on Immunization.
Meyer SA; Kambou JL; Cohn A; Goodson JL; Flannery B; Medah I; Messonnier N; Novak R; Diomande F; Djingarey MH; Clark TA; Yameogo I; Fall A; Wannemuehler K
Vaccine; 2015 Mar; 33(12):1492-8. PubMed ID: 25636915
[TBL] [Abstract][Full Text] [Related]
5. Serogroup A meningococcal conjugate vaccine coverage after the first national mass immunization campaign-Burkina Faso, 2011.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2012 Dec; 61(50):1022-4. PubMed ID: 23254256
[TBL] [Abstract][Full Text] [Related]
6. Preclinical immunogenicity and functional activity studies of an A+W meningococcal outer membrane vesicle (OMV) vaccine and comparisons with existing meningococcal conjugate- and polysaccharide vaccines.
Tunheim G; Arnemo M; Næss LM; Fjeldheim ÅK; Nome L; Bolstad K; Aase A; Mandiarote A; González H; González D; García L; Cardoso D; Norheim G; Rosenqvist E
Vaccine; 2013 Dec; 31(51):6097-106. PubMed ID: 24120679
[TBL] [Abstract][Full Text] [Related]
7. Antibody kinetics following vaccination with MenAfriVac: an analysis of serological data from randomised trials.
White M; Idoko O; Sow S; Diallo A; Kampmann B; Borrow R; Trotter C
Lancet Infect Dis; 2019 Mar; 19(3):327-336. PubMed ID: 30745277
[TBL] [Abstract][Full Text] [Related]
8. Human Complement Bactericidal Responses to a Group A Meningococcal Conjugate Vaccine in Africans and Comparison to Responses Measured by 2 Other Group A Immunoassays.
Price GA; Hollander AM; Plikaytis BD; Mocca BT; Carlone G; Findlow H; Borrow R; Sow SO; Diallo A; Idoko OT; Enwere GC; Elie C; Preziosi MP; Kulkarni PS; Bash MC
Clin Infect Dis; 2015 Nov; 61 Suppl 5():S554-62. PubMed ID: 26553688
[TBL] [Abstract][Full Text] [Related]
9. Antibody Persistence at 1 and 4 Years Following a Single Dose of MenAfriVac or Quadrivalent Polysaccharide Vaccine in Healthy Subjects Aged 2-29 Years.
Diallo A; Sow SO; Idoko OT; Hirve S; Findlow H; Preziosi MP; Elie C; Kulkarni PS; Parulekar V; Diarra B; Cheick Haidara F; Diallo F; Tapia M; Akinsola AK; Adegbola RA; Bavdekar A; Juvekar S; Chaumont J; Martellet L; Marchetti E; LaForce MF; Plikaytis BD; Enwere GC; Tang Y; Borrow R; Carlone G; Viviani S
Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S521-30. PubMed ID: 26553684
[TBL] [Abstract][Full Text] [Related]
10. Seroprevalence of bactericidal, specific IgG antibodies and incidence of meningitis due to group A Neisseria meningitidis by age in Burkina Faso 2008.
Trotter CL; Yaro S; Njanpop-Lafourcade BM; Drabo A; Kroman SS; Idohou RS; Sanou O; Bowen L; Findlow H; Diagbouga S; Gessner BD; Borrow R; Mueller JE
PLoS One; 2013; 8(2):e55486. PubMed ID: 23457471
[TBL] [Abstract][Full Text] [Related]
11. Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data.
Novak RT; Kambou JL; Diomandé FV; Tarbangdo TF; Ouédraogo-Traoré R; Sangaré L; Lingani C; Martin SW; Hatcher C; Mayer LW; Laforce FM; Avokey F; Djingarey MH; Messonnier NE; Tiendrébéogo SR; Clark TA
Lancet Infect Dis; 2012 Oct; 12(10):757-64. PubMed ID: 22818241
[TBL] [Abstract][Full Text] [Related]
12. Meningococcal carriage and immunity in western Burkina Faso, 2003.
Yaro S; Traoré Y; Tarnagda Z; Sangaré L; NjanpopLafourcade BM; Drabo A; Findlow H; Borrow R; Nicolas P; Gessner BD; Mueller JE
Vaccine; 2007 Sep; 25 Suppl 1():A42-6. PubMed ID: 17559988
[TBL] [Abstract][Full Text] [Related]
13. Development and use of a serum bactericidal assay using pooled human complement to assess responses to a meningococcal group A conjugate vaccine in African toddlers.
Bash MC; Lynn F; Mocca B; Borrow R; Findlow H; Hassan-King M; Preziosi MP; Idoko O; Sow S; Kulkarni P; Laforce FM
Clin Vaccine Immunol; 2014 May; 21(5):755-61. PubMed ID: 24671551
[TBL] [Abstract][Full Text] [Related]
14. Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity.
Kristiansen PA; Diomandé F; Ba AK; Sanou I; Ouédraogo AS; Ouédraogo R; Sangaré L; Kandolo D; Aké F; Saga IM; Clark TA; Misegades L; Martin SW; Thomas JD; Tiendrebeogo SR; Hassan-King M; Djingarey MH; Messonnier NE; Préziosi MP; Laforce FM; Caugant DA
Clin Infect Dis; 2013 Feb; 56(3):354-63. PubMed ID: 23087396
[TBL] [Abstract][Full Text] [Related]
15. Neisseria meningitidis serogroups A and W-135: carriage and immunity in Burkina Faso, 2003.
Mueller JE; Yaro S; Traore Y; Sangare L; Tarnagda Z; Njanpop-Lafourcade BM; Borrow R; Gessner BD
J Infect Dis; 2006 Mar; 193(6):812-20. PubMed ID: 16479516
[TBL] [Abstract][Full Text] [Related]
16. Effectively introducing a new meningococcal A conjugate vaccine in Africa: the Burkina Faso experience.
Djingarey MH; Barry R; Bonkoungou M; Tiendrebeogo S; Sebgo R; Kandolo D; Lingani C; Preziosi MP; Zuber PL; Perea W; Hugonnet S; Dellepiane de Rey Tolve N; Tevi-Benissan C; Clark TA; Mayer LW; Novak R; Messonier NE; Berlier M; Toboe D; Nshimirimana D; Mihigo R; Aguado T; Diomandé F; Kristiansen PA; Caugant DA; Laforce FM
Vaccine; 2012 May; 30 Suppl 2():B40-5. PubMed ID: 22607898
[TBL] [Abstract][Full Text] [Related]
17. Seroprevalence of antibodies against serogroup C meningococci in England in the postvaccination era.
Trotter CL; Borrow R; Findlow J; Holland A; Frankland S; Andrews NJ; Miller E
Clin Vaccine Immunol; 2008 Nov; 15(11):1694-8. PubMed ID: 18827191
[TBL] [Abstract][Full Text] [Related]
18. The impact of pre-existing antibody on subsequent immune responses to meningococcal A-containing vaccines.
Idoko OT; Okolo SN; Plikaytis B; Akinsola A; Viviani S; Borrow R; Carlone G; Findlow H; Elie C; Kulkarni PS; Preziosi MP; Ota M; Kampmann B
Vaccine; 2014 Jul; 32(33):4220-7. PubMed ID: 24863486
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the Impact of Meningococcal Serogroup A Conjugate Vaccine Introduction on Second-Year-of-Life Vaccination Coverage in Burkina Faso.
Zoma RL; Walldorf JA; Tarbangdo F; Patel JC; Diallo AO; Nkwenkeu SF; Kambou L; Nikiema M; Ouedraogo A; Bationo AB; Ouili R; Badolo H; Sawadogo G; Krishnaswamy A; Hatcher C; Hyde TB; Aké F; Novak RT; Wannemuehler K; Mirza I; Medah I; Soeters HM
J Infect Dis; 2019 Oct; 220(220 Suppl 4):S233-S243. PubMed ID: 31671442
[TBL] [Abstract][Full Text] [Related]
20. Persistent low carriage of serogroup A Neisseria meningitidis two years after mass vaccination with the meningococcal conjugate vaccine, MenAfriVac.
Kristiansen PA; Ba AK; Ouédraogo AS; Sanou I; Ouédraogo R; Sangaré L; Diomandé F; Kandolo D; Saga IM; Misegades L; Clark TA; Préziosi MP; Caugant DA
BMC Infect Dis; 2014 Dec; 14():663. PubMed ID: 25472422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]